Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...

Evercore ISI upgraded BioNTech (BNTX) to Outperform from In Line with a price target of $125, up from $110. The firm says it has been “growing increasingly constructive for some time now.” The upgrade ...

Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...

BioNTech (NASDAQ:BNTX) stock rose 1.9% after Evercore ISI upgraded its stance on the drugmaker to ‘outperform’ from ‘in line’ ...

LONDON — Robert F. Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says ...

Trump Suggests Use of Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...

BioNTech buys Biotheus and its Keytruda rival for $950m Chasing $80bn sales target, AZ unveils $3.5bn US investment News London "is number one European city in life sciences" ...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery.